ACTG news release
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced the opening of A5432, a study assessing factors that may affect how long-acting antiretroviral therapy (ART) is used and researched among people living with HIV who previously have been unable to maintain viral suppression on a daily oral ART regimen. A5432 is an exploratory study that utilizes several qualitative methods to better understand the experiences of participants and staff who were part of the LATITUDE study (also known as A5359), in order to design future studies and support broader uptake of long-acting ART among this population.
LATITUDE was a landmark ACTG trial finding that long-acting ART suppressed HIV replication better than a daily regimen among people living with HIV who were not virally suppressed on daily ART (a group that represents approximately one-third of people on ART).
Read the full news release here.
Source : GLOBE NEWSWIRE
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.